- Home
- ENX vs SKYE Comparison
ENX vs SKYE Comparison
Compare ENX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- SKYE
- Stock Information
- Founded
- ENX 2002
- SKYE 2012
- Country
- ENX United States
- SKYE United States
- Employees
- ENX N/A
- SKYE N/A
- Industry
- ENX Finance/Investors Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ENX Finance
- SKYE Health Care
- Exchange
- ENX Nasdaq
- SKYE Nasdaq
- Market Cap
- ENX 175.5M
- SKYE 94.0M
- IPO Year
- ENX N/A
- SKYE N/A
- Fundamental
- Price
- ENX $9.48
- SKYE $2.73
- Analyst Decision
- ENX
- SKYE Buy
- Analyst Count
- ENX 0
- SKYE 6
- Target Price
- ENX N/A
- SKYE $18.67
- AVG Volume (30 Days)
- ENX 25.4K
- SKYE 167.7K
- Earning Date
- ENX 01-01-0001
- SKYE 02-09-2025
- Dividend Yield
- ENX 3.94%
- SKYE N/A
- EPS Growth
- ENX N/A
- SKYE N/A
- EPS
- ENX 0.16
- SKYE N/A
- Revenue
- ENX N/A
- SKYE N/A
- Revenue This Year
- ENX N/A
- SKYE N/A
- Revenue Next Year
- ENX N/A
- SKYE N/A
- P/E Ratio
- ENX $61.00
- SKYE N/A
- Revenue Growth
- ENX N/A
- SKYE N/A
- 52 Week Low
- ENX $7.84
- SKYE $2.25
- 52 Week High
- ENX $10.07
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- ENX 41.09
- SKYE 37.40
- Support Level
- ENX $9.42
- SKYE $2.31
- Resistance Level
- ENX $9.89
- SKYE $3.04
- Average True Range (ATR)
- ENX 0.12
- SKYE 0.30
- MACD
- ENX -0.01
- SKYE 0.07
- Stochastic Oscillator
- ENX 29.35
- SKYE 44.68
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.